根据现实世界监测数据估计的针对COVID-19严重急性呼吸道感染(SARI)住院的疫苗有效性，斯洛文尼亚，2021年10月。

IF 7.8

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin Pub Date : 2022-01-01 DOI:10.2807/1560-7917.ES.2022.27.1.2101110

Marta Grgič Vitek, Irena Klavs, Veronika Učakar, Mojca Serdt, Maja Mrzel, Marjana Vrh, Mario Fafangel

{"title":"根据现实世界监测数据估计的针对COVID-19严重急性呼吸道感染(SARI)住院的疫苗有效性，斯洛文尼亚，2021年10月。","authors":"Marta Grgič Vitek, Irena Klavs, Veronika Učakar, Mojca Serdt, Maja Mrzel, Marjana Vrh, Mario Fafangel","doi":"10.2807/1560-7917.ES.2022.27.1.2101110","DOIUrl":null,"url":null,"abstract":"We estimated vaccine effectiveness (VE) against severe COVID-19 during October 2021, using Slovenian surveillance data. For people fully vaccinated with any vaccine in age groups 18-49, 50-64, ≥ 65 years, VE was 86% (95% CI: 79-90), 89% (85-91), and 77% (74-81). Among ≥ 65 year-olds fully vaccinated with mRNA vaccines, VE decreased from 93% (95% CI: 88-96) in those vaccinated ≤ 3 months ago to 43% (95% CI: 30-54) in those vaccinated ≥ 6 months ago, suggesting the need for early boosters.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739341/pdf/","citationCount":"5","resultStr":"{\"title\":\"Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.\",\"authors\":\"Marta Grgič Vitek, Irena Klavs, Veronika Učakar, Mojca Serdt, Maja Mrzel, Marjana Vrh, Mario Fafangel\",\"doi\":\"10.2807/1560-7917.ES.2022.27.1.2101110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We estimated vaccine effectiveness (VE) against severe COVID-19 during October 2021, using Slovenian surveillance data. For people fully vaccinated with any vaccine in age groups 18-49, 50-64, ≥ 65 years, VE was 86% (95% CI: 79-90), 89% (85-91), and 77% (74-81). Among ≥ 65 year-olds fully vaccinated with mRNA vaccines, VE decreased from 93% (95% CI: 88-96) in those vaccinated ≤ 3 months ago to 43% (95% CI: 30-54) in those vaccinated ≥ 6 months ago, suggesting the need for early boosters.\",\"PeriodicalId\":520613,\"journal\":{\"name\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739341/pdf/\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

摘要

我们利用斯洛文尼亚的监测数据估计了2021年10月期间疫苗对严重COVID-19的有效性。在18-49岁、50-64岁和≥65岁年龄组完全接种任何一种疫苗的人群中，VE为86% (95% CI: 79-90)、89%(85-91)和77%(74-81)。在完全接种mRNA疫苗的≥65岁的人群中，VE从≤3个月前接种者的93% (95% CI: 88-96)下降到≥6个月前接种者的43% (95% CI: 30-54)，表明需要早期增强剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.

We estimated vaccine effectiveness (VE) against severe COVID-19 during October 2021, using Slovenian surveillance data. For people fully vaccinated with any vaccine in age groups 18-49, 50-64, ≥ 65 years, VE was 86% (95% CI: 79-90), 89% (85-91), and 77% (74-81). Among ≥ 65 year-olds fully vaccinated with mRNA vaccines, VE decreased from 93% (95% CI: 88-96) in those vaccinated ≤ 3 months ago to 43% (95% CI: 30-54) in those vaccinated ≥ 6 months ago, suggesting the need for early boosters.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

自引率

0.00%

发文量